Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,835 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $33.81, for a total transaction of $433,951.35. Following the sale, the chief financial officer now owns 25,767 shares in the company, valued at approximately $871,182.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Intersect ENT Inc (XENT) opened at $34.35 on Friday. Intersect ENT Inc has a fifty-two week low of $11.75 and a fifty-two week high of $35.34. The stock has a market cap of $1,020.65, a P/E ratio of -54.52 and a beta of 0.67.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The company had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. During the same quarter last year, the company posted ($0.22) earnings per share. The firm’s quarterly revenue was up 20.8% on a year-over-year basis. analysts forecast that Intersect ENT Inc will post -0.63 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Great West Life Assurance Co. Can purchased a new stake in Intersect ENT in the third quarter worth approximately $116,000. Oppenheimer Asset Management Inc. bought a new position in Intersect ENT in the third quarter worth approximately $117,000. Legal & General Group Plc raised its position in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after acquiring an additional 255 shares during the period. Moors & Cabot Inc. bought a new position in Intersect ENT in the second quarter worth approximately $205,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Intersect ENT in the third quarter worth approximately $228,000. Institutional investors own 86.31% of the company’s stock.
A number of research firms have recently commented on XENT. BidaskClub upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Saturday, December 30th. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a report on Thursday, October 5th. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities restated a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. Finally, Guggenheim restated a “buy” rating and issued a $41.00 target price on shares of Intersect ENT in a report on Friday, December 15th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $33.38.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.